CD8A and neoplasm: Importantly, there is temporal heterogeneity in the response of Teff cells to CB-839 treatment, and others have shown that short-term ex vivo treatment of Teff cells with CB-839 enhanced the subsequent anti-tumor function of Th1 cells and CD8+ CTLs in vivo.